Merck Closes In On Acceleron But BMS And Anti-Trust Regulators Could Be Obstacles
Bidding War May Ensue
Biopharma M&A has had a quiet year so far but could heat up if rivals start vying for the biotech company.
You may also be interested in...
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.
With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.